A systematic screen of 21 snake and arthropod venoms on human joint cells found that scorpion Buthus occitanus venom uniquely induced anti-inflammatory IL-10 without triggering inflammatory cytokines — a promising lead for joint disease treatment.
21 venoms, 4 cell typesSystematic screening identified scorpion Buthus occitanus venom as uniquely anti-inflammatory — inducing IL-10 without triggering pro-inflammatory cytokines in macrophages
What the researchers found
At non-cytotoxic concentrations, most of the 21 tested venoms activated inflammatory mediator release: IL-6, IL-8, and TNF-α from chondrocytes, synoviocytes, and macrophages, and substance P from neuron-like cells. Viperidae snake venoms were more inflammatory than Elapidae venoms, and arthropod venoms were generally less inflammatory than snake venoms.
Notably, some venoms induced IL-10 (anti-inflammatory) release from macrophages. The scorpion Buthus occitanus venom was unique — it induced IL-10 release without increasing inflammatory cytokine production from macrophages, making it the most promising candidate for anti-inflammatory drug discovery. The platform also measured neuropeptide release (substance P and β-endorphin) from differentiated sensory neuron-like cells, connecting venom effects to pain modulation pathways.
Why it matters
Inflammatory joint diseases affect hundreds of millions of people worldwide, and current treatments often fail to achieve remission. Animal venoms contain thousands of bioactive peptides and proteins optimized by evolution, but their effects on joint-specific cells had never been systematically studied. This screening platform identifies which venoms — and eventually which specific compounds within them — have the best therapeutic potential, focusing research efforts on the most promising candidates like the Buthus occitanus scorpion venom.
How the study worked
Twenty-one venoms from snake and arthropod species across different taxonomic families and geographic origins were tested. A cell-based assay platform was established using human chondrocytes, synoviocytes, THP1 macrophages, and differentiated sensory neuron-like cells. Cells were stimulated with venoms at non-cytotoxic concentrations for 24 hours. Cytokine release (IL-6, IL-8, TNF-α, IL-1β, IL-10) and neuropeptide release (substance P, β-endorphin) were measured.
What this study cannot tell us
This is an in vitro screening study — no animal or human therapeutic testing was performed. The study tested whole venoms, not individual peptide or protein components, so the specific bioactive molecules responsible for the observed effects are unknown. The 24-hour exposure period may not reflect chronic inflammatory disease conditions. Cell lines and primary cells in culture may not fully replicate the complex joint microenvironment. The non-cytotoxic concentrations used may differ from therapeutically relevant doses.
How to read the evidence
This is an in vitro screening study that establishes a discovery platform and identifies candidates for further investigation. While the systematic approach across 21 venoms and 4 cell types is comprehensive, this represents early-stage drug discovery with no in vivo validation or therapeutic testing.
When this study was published
Published in 2024 in Toxicon, this study is recent and aligns with growing interest in venom-derived therapeutics. The screening platform could be applied to additional venoms as they become available.
The bigger picture
Venom-derived drugs have a proven track record — captopril (from snake venom) revolutionized blood pressure treatment, and exenatide (from Gila monster venom) pioneered GLP-1 therapy. This systematic screening of 21 venoms on joint-relevant cells represents the first step in a similar discovery pipeline for inflammatory joint disease. The inclusion of neuropeptide measurements adds a pain dimension that most venom screens miss, recognizing that effective arthritis treatment must address both inflammation and pain.
Questions still open
- Which specific peptide or protein component within Buthus occitanus venom is responsible for the selective IL-10 induction?
- Could the anti-inflammatory venom components be isolated and developed into injectable treatments for rheumatoid arthritis or osteoarthritis?
- How do the neuropeptide effects (substance P, β-endorphin) relate to the pain experience in joint disease — could venom components modulate both inflammation and pain?
Common questions
How could scorpion venom help with arthritis?
Why test venoms on joint cells specifically?
Read the original research
Snake and arthropod venoms: Search for inflammatory activity in human cells involved in joint diseases.
Toxicon : official journal of the International Society on Toxinology, 238, 107568
Citation
Alvarez-Flores, Miryam Paola; Correia Batista, Isabel de Fatima; Villas Boas, Isadora Maria; Bufalo, Michelle Cristiane; de Souza, Jean Gabriel; Oliveira, Douglas Souza; Bonfá, Giuliano; Fernandes, Cristina Maria; Marques Porto, Rafael; Lichtenstein, Flavio; Picolo, Gisele; Tambourgi, Denise V; Chudzinski-Tavassi, Ana Marisa; Ibañez, Olga Célia Martinez; Teixeira, Catarina. (2024). Snake and arthropod venoms: Search for inflammatory activity in human cells involved in joint diseases.. Toxicon : official journal of the International Society on Toxinology, 238, 107568. https://doi.org/10.1016/j.toxicon.2023.107568